Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) EBIT (2020 - 2025)

Historic EBIT for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.

  • RxSight's EBIT fell 3199.65% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.5 million, marking a year-over-year decrease of 1638.14%. This contributed to the annual value of -$36.9 million for FY2024, which is 2640.91% up from last year.
  • As of Q3 2025, RxSight's EBIT stood at -$12.2 million, which was down 3199.65% from -$14.0 million recorded in Q2 2025.
  • RxSight's 5-year EBIT high stood at -$8.3 million for Q2 2024, and its period low was -$16.6 million during Q1 2022.
  • For the 5-year period, RxSight's EBIT averaged around -$12.6 million, with its median value being -$13.1 million (2023).
  • As far as peak fluctuations go, RxSight's EBIT tumbled by 7662.01% in 2021, and later soared by 3884.04% in 2024.
  • Quarter analysis of 5 years shows RxSight's EBIT stood at -$14.7 million in 2021, then dropped by 2.23% to -$15.0 million in 2022, then increased by 27.61% to -$10.9 million in 2023, then increased by 20.49% to -$8.6 million in 2024, then plummeted by 41.15% to -$12.2 million in 2025.
  • Its last three reported values are -$12.2 million in Q3 2025, -$14.0 million for Q2 2025, and -$10.7 million during Q1 2025.